MAPT and Alzheimer disease: 2020; Frisoni et al. 2010). Proteins present in CSF or blood, such as low Aβ(1–42) levels and increased total or phosphorylated tau (p‐tau) levels, are also regularly used as biomarkers for the diagnosis of cognitive impairments linked to AD (Hampel and Blennow 2004). The identification of sensitive biomarkers that reflect the pre‐symptomatic neurodegenerative changes remains essential. Testing different biomarkers from both CSF and blood can yield more accurate results (Alawode et al. 2021).